NCT05769595View on ClinicalTrials.gov

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions
End-Stage Renal Disease (ESRD)End-Stage Kidney Disease (ESKD)Kidney Failure, Chronic
Interventions
BIOLOGICAL

MK-2060

Lyophilized powder diluted in normal saline for IV infusion

DRUG

Placebo

IV infusion

Trial Locations (12)

486-8510

Kasugai Municipal Hospital ( Site 1203), Kasugai

455-8530

Chubu Rosai Hospital ( Site 1202), Nagoya

457-8511

Kojunkai Daido Hospital ( Site 1207), Nagoya

371-0046

Jomo Ohashi Clinic ( Site 1210), Maebashi

309-1793

Ibaraki Prefectural Central Hospital ( Site 1211), Kasama

247-8533

Shonan Kamakura General Hospital ( Site 1205), Kamakura

390-1401

Matsumoto City Hospital ( Site 1209), Matsumoto

874-0937

Keiaikai Nakamura Hospital ( Site 1213), Beppu

525-8585

Omi Fureai Hospital ( Site 1204), Kusatsu

146-8531

Ikegami General Hospital ( Site 1206), Ōta-ku

815-8555

Japanese Red Cross Fukuoka Hospital ( Site 1214), Fukuoka

990-0834

Yamagata Tokushukai Hospital ( Site 1201), Yamagata

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05769595 - Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012) | Biotech Hunter | Biotech Hunter